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Spinal muscular atrophy (SMA) is the leading genetic cause 
of infant mortality. Most SMA cases are associated with the 
low levels of SMN owing to deletion of Survival Motor Neuron 
1 (SMN1). SMN2, a nearly identical copy of SMN1, fails to 
compensate for the loss of SMN1 due to predominant skipping 
of exon 7. Hence, correction of aberrant splicing of SMN2 exon 
7 holds the potential for cure of SMA. Here we report an 8-mer 
antisense oligonucleotide (ASO) to have a profound stimulatory 
response on correction of aberrant splicing of SMN2 exon 7 by 
binding to a unique GC-rich sequence located within intron 
7 of SMN2. We confirm that the splicing-switching ability of 
this short ASO comes with a high degree of specificity and 
reduced off-target effect compared to larger ASOs targeting 
the same sequence. We further demonstrate that a single low 
nanomolar dose of this 8-mer ASO substantially increases 
the levels of SMN and a host of factors including Gemin 2, 
Gemin 8, ZPR1, hnRNP Q and Tra2-b1 known to be down-
regulated in SMA. Our findings underscore the advantages and 
unmatched potential of very short ASOs in splicing modulation 
in vivo.
Introduction
Alternative splicing is an essential process in the generation 
of protein diversity and has been a major contributory force 
to genome evolution.1 Splicing is catalyzed by a spliceosome, 
a complex macromolecular machine.2,3 However, control of 
alternative splicing rests on non-spliceosomal factors that bind to 
pre-mRNA sequences called exonic or intronic splicing enhancers 
(ESEs or ISEs) and silencers (ESSs or ISSs).4-6 Enhancer and 
silencer motifs promote or suppress splice-site (ss) selection, respec-
tively. Methods to decipher critical splicing motifs are continuing 
to evolve.7-10 An additional regulatory role is provided by RNA 
structures that enforce accessibility to splicing elements, as well as 
bring two distantly located cis-elements into close proximity.11-14 
Alternative splicing has been implicated in a growing number of 
human diseases.15 In this regard antisense oligonucleotides (ASOs) 
targeting regulatory elements have emerged as the powerful tools 
to modulate alternative splicing in pathological conditions.15-19
Humans have two nearly identical copies of the Survival Motor 
Neuron (SMN) gene: SMN1 and SMN2.20 The two SMN genes 
code for identical proteins, however, SMN2 predominantly gener-
ates a short transcript due to skipping of exon 7, producing a 
truncated SMN that is highly unstable.21 Other non-productive 
SMN2 mRNAs lacking exons 5 and 3 have also been reported.22 
The inability of SMN2 to compensate for the loss of SMN1 results 
in spinal muscular atrophy (SMA), a debilitating disease of children 
and infants.15,16,23 Further, low levels of SMN are also associated 
with certain forms of amyotrophic lateral sclerosis (ALS), a progres-
sive neurological disease that attacks the nerve cells responsible 
for controlling voluntary muscles.24,25 SMN is a housekeeping 
protein, with its most important function being the assembly of 
U snRNPs, the essential components of the spliceosomal 
machinery.26 Consistently, depletion of SMN causes tissue-specific 
perturbations in the repertoire of snRNAs and widespread defects 
in splicing.27 Other important functions associated with SMN 
include transcriptional regulation, telomerase regeneration and 
cellular trafficking.28 Consistently, higher organisms lacking SMN 
are not viable.28
SMN1 and SMN2 differ by a critical C to T substitution at 
position 6 (C6U transition) of exon 7 in SMN2.29 The signifi-
cance of an additional difference within intron 7 of SMN1 and 
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We performed our experiments in commercially available SMA 
type I patient cells (GM03813), which serves as an ideal system 
for testing of splicing-correcting compounds in the context of the 
disease caused by the lack of SMN1.39,42,43
Our ultra-refined antisense microwalk used four groups of ASOs 
of varying sizes. The ASOs from each group sequestered 0, 1, 2 or 
3 residues upstream of ISS-N1. Accordingly, ASOs were named 
as F, 1UP, 2UP and 3UP, followed by a number representing the 
size of the ASO (Table 1). To discriminate between the most and 
the least efficient ASOs, the antisense microwalk was performed 
at four concentrations: 1 nM, 10 nM, 50 nM and 100 nM 
(Table 1). Figure 1 shows the splicing pattern of representative 
ASOs performed at 20 nM. We observed a decrease in the anti-
sense effect on exon 7 inclusion with a decrease in the size of F, 
1UP and 2UP ASOs (Table 1, Fig. 1B). However, the results were 
drastically different with 3UP ASOs: shortening of ASOs from 
14 nucleotides to 8 nucleotides produced no significant changes 
in their stimulatory effects on exon 7 splicing (Fig. 1B). However, 
the stimulatory effect drastically decreased when ASO size was 
further reduced from 8 nucleotides to 7 nucleotides. Hence, we 
conclude that the shortest ASO to effectively restore SMN2 exon 
7 inclusion was 3UP8, an 8-mer ASO that sequestered the entire 
octamer sequence, CUGCCAGC, discussed above. Remarkably, 
3UP8 was able to fully restore SMN2 exon 7 inclusion at a rela-
tively low concentration of 50 nM (Table 1).
The finding that 3UP8 restores SMN2 exon 7 inclusion marks 
the discovery of the shortest ASO among ~200 ASOs tested thus 
far in SMA patient cells (Table 1).39,42-49 In addition to revealing 
the shortest stimulatory ASO, the ultra-refined microwalk was 
able to accurately define the first five residues (CCAGC) of 
ISS-N1 as the core sequence of the antisense target. Our finding 
of core sequence brings a parallel with seed sequence required for 
miRNA and siRNA response.50 Similar to seed sequence, seques-
tering of the core sequence was essential but not sufficient for the 
antisense response. In addition to sequestration of core sequence, 
sequestration of additional three residues (CUG) upstream of 
ISS-N1 was found to be essential to obtain the shortest stimula-
tory ASO. In the absence of the sequestration of CUG residues, an 
11-nucleotide or longer target was required for realizing the stimu-
latory response (Table 1). Underscoring the overlapping nature of 
splicing cis-elements and their hard-to-predict accessibility during 
the dynamic process of splicing, we found no direct correlation 
between the size of ASOs and their stimulatory response. Similarly, 
we found no direct correlation between sequestration of any of 
the individual hnRNP A1 motifs and the level of stimulatory 
response. For instance, F10 and L13 fully sequestered the 1st and 
the 2nd hnRNP A1 motifs, respectively, and yet did not produce 
any significant stimulatory response even at higher concentration 
of 100 nM (Table 1). On the other hand, 3UP8 restored SMN2 
exon 7 by sequestering an 8-mer motif that only partially overlaps 
the first hnRNP A1 motif.
Antisense effect is specific to base paring with the target. 
Having discovered that a short intronic motif could be targeted 
for splicing modulation of endogenous pre-mRNA, we next 
examined the efficacy and specificity of short ASO in SMN2 
SMN2 has been reported.30 Both SMN1 and SMN2 share the 
same branch site for the lariat formation during the removal 
of intron 6.31 Yet C6U weakens the 3'-splice site (3' ss) of 
exon 7 in SMN2.32 Published reports suggest C6U abrogates 
an enhancer and/or creates a silencer.33-36 In vivo selection 
of the entire exon revealed three major cis-elements within 
exon 7.37 Two of them, “Exinct” and “3'-Cluster,” are negative 
regulators of splicing. They flank “Conserved Tract”, the positive 
element located in the middle of exon 7.29 The identification of 
“Conserved Tract” is in agreement with the role of the previously 
reported Tra2-b1-associated enhancer.38 Recently, an antisense 
micro-walk within exon 7 independently supported the nature of 
these three cis-elements.39 Several intronic cis-elements have been 
implicated in regulation of SMN2 exon 7 splicing as well.30,40-43
Since SMN2 is almost universally present in SMA patients, 
correction of SMN2 exon 7 splicing using target-specific ASOs 
holds the promise for cure. A number of studies have focused on 
use of large ASOs with bifunctional properties to restore SMN2 
exon 7 inclusion.44-47 Other studies have focused on targeting 
large regulatory motifs or a combination of regulatory motifs to 
induce SMN2 exon 7 inclusion.39,42,43,48,49 However, it is not 
known if sequestering of a short splicing motif by a short ASO 
could prevent exon skipping and restore SMN2 exon 7 inclusion. 
Here we report the splicing-switching ability of an 8-mer ASO that 
binds to a unique regulatory sequence and fully restores SMN2 
exon 7 inclusion. We also demonstrate that this 8-mer ASO offers 
a high degree of specificity and reduced off-target effect compared 
to larger ASOs targeting the same region. Considering short ASOs 
offer several advantages including low cost of synthesis, ease of 
chemical modifications, reduced chances of immune response, 
and higher probability of crossing biological barriers, our findings 
serve as a major step forward for splicing modulation in a genetic 
disease.
Results
An ultra-refined antisense microwalk revealed shortest motif for 
splicing correction. Recent reports have confirmed the presence of 
a negative context located downstream of the 5' splice site (5' ss) of 
SMN2 exon 7.42,43 This negative context is defined by a 15-nuclei-
otide cis-element, ISS-N1 that harbors two putative hnRNP A1/A2 
motifs (Fig. 1A).42,43 ISS-N1 partially overlaps with an octamer 
sequence CUGCCAGC, which is the only GC-rich sequence in 
the first half of the intron 7 of human SMN. This sequence is 
predicted to reside in a single-stranded region sandwiched between 
two stem-loop structures (Fig. 1A).28 Combined with an easy 
accessibility and the high GC-rich content (75%), this octamer 
sequence has a potential to provide an ideal ASO target. However, 
it is not known if a short RNA:RNA duplex formed between 
CUGCCAGC and an ASO could displace an interacting protein 
and/or drastically change the negative context to reverse the splicing 
pattern. To explore such possibility, we performed an ultra-refined 
antisense microwalk downstream of the 5' ss of SMN2 exon 7. All 
ASOs used in our study incorporated 2'-O-methyl modification 
and phosphorothioate backbone (abbreviated as “2OMePS”), a 
widely used RNA modification with proven stability in vivo.16,18,19 
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ASO (3UP8) lost all its stimulatory response in SMN2/64A. 
As expected, a mutant 8-mer ASO (3UP8/64A) that reinstated the 
base pairing with the mutated target fully restored exon 7 inclu-
sion in SMN2/64A minigene; at the same time 3UP8/64A had no 
stimulatory effect on splicing of SMN2 minigene (Fig. 2B). Note 
that the stimulatory impact of 3UP8/64A in SMN2/64A minigene 
was realized despite the fact that the C-to-A mutation reduced 
the GC content of the target from 75% to 62.5%. Unlike 8-mer 
ASOs, all four 15-mer ASOs we used effectively restored exon 
7 inclusion in SMN2/64A. These results clearly suggest that an 
increase in ASO size could have drastic (negative) consequences on 
minigene system. Here HeLa cells were co-transfected with the 
minigene (0.1 mg) and an ASO of interest (50 nM) and the effect 
on splicing was accessed by RT-PCR. As shown in Figure 2B, 
the ASO effect on splicing of minigene-derived exon 7 was 
consistent with the results for the endogenous SMN2 with 
3UP8 being the shortest ASO to fully restore exon 7 inclusion. 
To compare the target specificity between long and short ASOs, 
we generated a mutant minigene, SMN2/64A. This minigene 
has a single C to A substitution at the first position of ISS-N1, 
hence has capability to weaken the RNA:RNA duplex between 
the antisense and the target (Fig. 2A). Indeed, our shortest 
Figure 1. Untra-refined antisense microwalk to identify the shortest stimulatory ASO. (A) Diagrammatic representation of ASOs targeting sequences 
upstream of ISS-N1. Exon 7 is boxed and the first 24 residues of human SMN intron 7 are shown. Numbering starts from the first position of intron 7. 
The 5' ss of exon 7 is indicated by a vertical arrow. ASOs blocking different regions are shown as horizontal bars. Sequences of these ASOs are given 
in Table 1. Boundary of ISS-N1 is demarcated.42 hnRNP A1 motifs are indicated.43 Green bars represent ASOs that promote SMN2 exon 7 inclusion. 
Intensity of green color reflects the strength of stimulatory effect. Tan bars represent ASOs that have no effect on SMN2 exon 7 inclusion. Area highlighted 
in pink represents the only GC-rich sequence in the first half of human intron 7. Area highlighted in light blue represents the core sequence of the antisense 
target. Right panel shows the relative positioning of ISS-N1, GC-rich sequence in the context of predicted RNA structure. Green bar represents 3UP8, the 
shortest ASO to stimulate SMN2 exon 7 inclusion. (B) Splicing pattern of endogenous SMN2 in SMA type I patient fibroblasts (GM03813) treated with 
different ASOs. Cells were transfected with 20 nM of 2OMePS ASOs and the total RNA for splicing assay was isolated 24 h post transfection. Results 
were analyzed as described earlier.35 3UP8 was the shortest ASO to show stimulatory response (highlighted by green box).
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Table 1 Effect of ASOs on skipping of SMN2 exon 7 in SMA type I fibroblasts (GM03183)
Cells were transfected with 1, 10, 50 and 100 nM of ASOs and the total RNA for splicing assay was isolated 24 h post transfection. First 29 residues of intron 7 of human SMN are shown in small-case letters. 
Numbering starts from position 1 of intron 7. GC-rich sequence is highlighted in pink. Positions of ISS-N1 residues are boxed. Two hnRNP A1 motifs within ISS-N1 are indicated.43 First five residues of ISS-N1 
constitute the core of the antisense target and are marked as “CORE” and highlighted in blue. Sequences of ASOs are shown in large case letters in 3' to 5' direction and are arranged against the target sequence 
of intron 7. Percentage of SMN2 exon 7 skipping is shown on the right. Values highlighted in blue, green and light green colors represent 10% or less, 25% or less and 40% or less exon 7 skipping, respectively. 
Values highlighted in tan color represent no appreciable effect on SMN2 exon 7 splicing. Mock transfection (without any ASO) produced 50% of SMN2 exon 7 skipping.
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with another primer pair that annealed to exons 
4 and 6. We found no significant difference on 
effect on exon 5 splicing in cells treated with any 
of the tested ASOs (Fig. 3B). To monitor skip-
ping of SMN2 exon 3, we used a forward primer 
that annealed to exon 1 and the reverse primer 
that annealed to exon 4. As shown in Figure 3C, 
F14 and 3UP8 produced no detectable change 
in the level of exon 3 skipping as compared 
to the mock-transfected sample. Contrary to 
this, Anti-N1 produced a substantial increase in 
SMN2 exon 3 skipping at 100 nM (Fig. 3C). 
Mechanism by which Anti-N1 elicits this off-
target effect is not understood, although it clearly 
underscores the disadvantage of long ASOs as the 
therapeutic molecules.
Restoration of SMN levels by shortest ASO 
in SMA patient cells. The next goal of our study 
was to determine whether the correction of 
SMN2 exon 7 splicing by 3UP8 resulted in SMN 
protein increase in patient cells. In particular, 
we wanted to compare the stimulatory effect of 
3UP8 with a longer ASO, Anti-N1. F8 served 
as the negative control. The experiments were 
performed with 40 nM of a given ASO and 
protein levels were determined 48 hours after 
transfection. Simultaneously, we monitored the 
levels of SMN2 exon 7 inclusion. As shown in 
Figure 4A, mock-treatment (mock) or treatment with F8 did not 
produce any change in SMN levels (left) as well as in levels of 
SMN2 exon 7 inclusion (right). In contrast, treatment with 3UP8 
resulted in a substantial upregulation of SMN levels (Fig. 4A, left) 
and SMN2 exon 7 inclusion (Fig. 4A, right). Significantly, the effect 
of 3UP8 on SMN levels was comparable to the effect produced by 
Anti-N1 treatment. To determine whether increase in SMN levels 
in ASO-treated patient cells was accompanied by a change in 
cellular metabolism, we performed western blot for a number of 
proteins that are generally downregulated in SMA. As shown in 
Figure 4A (left), treatment of patient cells with 3UP8 was accom-
panied by a marked increase in the levels of Gemin 2 and Gemin 
8. These factors are associated with SMN complex, a macromol-
ecule essential for the housekeeping role of snRNP biogenesis.26,27 
We also observed an increase in the levels of ZPR1 (Fig. 4A), another 
SMN-interacting protein, reduced expression of which is associ-
ated with the progressive loss of motor neurons.51,52 Interestingly, 
the correction of splicing by 3UP8 resulted in increase of levels of 
splicing factors Tra2-b1 and hnRNP Q. Tra2-b1 and hnRNP Q1 
isoform have been shown to promote SMN2 exon 7 inclusion and 
are generally downregulated in SMA.38,53-55 Thus, our findings 
suggest that SMN may be a part of a positive feedback loop that 
provides signals to increase the levels of different splicing factors.
Cell division and degradation of ASOs are bound to attenuate 
the stimulatory effect of ASOs with respect to time. To determine 
the sustainability of a single 3UP8 treatment, we performed a time 
course analysis in which levels of SMN and other factors were 
the specificity of the antisense response since longer ASO appear to 
be more “tolerant” to single-nucleotide mismatches.
The shortest stimulatory ASO has no off-target effect on 
other SMN2 exons. To examine the possible off-target effect of 
ASOs that promote SMN2 exon 7 inclusion in GM03813 cells, 
we focused on splicing of SMN2 exons 3 and 5. These exons are 
known to undergo alternative splicing;22 and therefore, have a 
potential to regulate the levels of full-length SMN. We have earlier 
reported that a 5 nM concentration of Anti-N1 had no detect-
able effect on splicing pattern of SMN2 exons 3 and 5.42 Here we 
increased the ASO concentration to 20 and 100 nM. We chose to 
use Anti-N1, F14 and 3UP8 to represent the longest, the interme-
diate and the shortest stimulatory ASO, respectively. F8 served as 
a negative control.
We started with the amplification of endogenous SMN2-spliced 
products using a pair of primers located within exons 4 and 8. 
This primer combination provided an added advantage of simul-
taneous detection of skipping of exons 5 and 7. To compare the 
amount of the spliced products in broad size range, we used an end-
labeled primer. As shown in Figure 3A, all three functional ASOs: 
Anti-N1, F14 and 3UP8, were highly efficient in promoting exon 
7 inclusion at 20 nM concentration, while F8 produced no effect. 
None of the ASOs appeared to have a pronounced effect on splicing 
of exon 5 at both ASO concentrations. At the same time, Anti-N1, 
F14 and 3UP8 caused a decrease in the amount of the co-exclu-
sion product (mRNAs lacking both exons 5 and 7), especially at 
100 nM (Fig. 3A). Skipping of exon 5 was separately measured 
Figure 2. Antisense effect is specific to its target sequence. (A) Diagrammatic representation 
of intron 7 of SMN2 minigene and its mutant, SMN2/64A. Numbering starts from the first 
position of human SMN intron 7. ISS-N1 sequence is highlighted in gray. Mutated residue 
is highlighted in black. (B) Effect of ASOs on splicing of SMN2 minigene and its mutant, 
SMN2/64A. HeLa cells were transfected with 50 nM of a given ASO and 0.1 mg of minigene 
in a 24-well plate. Splicing was determined 24 h after transfection. Results were analyzed as 
described earlier.35
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It is possible that increase in Tra2-b1 and hnRNP Q levels contrib-
uted to exon 7 inclusion.
SMA patient cells are usually deficient in SMN-containing sub-
nuclear bodies or gems. To test whether increase in SMN levels can 
induce its nuclear accumulation in gems, we performed immuno-
fluorescence analysis of 3UP8 treated GM03813 cells. Here F8 
was used as a negative control. As shown in Figure 5, transfection 
of cells with 3UP8 was accompanied by a profound increase in the 
number of gems containing SMN. We also observed that 3UP8 
but not F8 resulted in increase and redistribution to gems of 
examined at 24 hr intervals for six days. Simultaneously, we also 
monitored ASO effect on SMN2 exon 7 splicing. A single dose of 
40 nM of 3UP8 was sufficient to sustain the increased levels of 
SMN for five days (Fig. 4B, left). Effect on other proteins varied 
with respect to time. For example, levels of Gemin 2, Gemin 8, 
ZPR1 and hnRNP Q peaked at day three but started decreasing 
after that, whereas the levels of Tra2-b1 reached maximum on 
day three and remained high till day five (Fig. 4B, left). As for 
the effect on exon 7 splicing, levels of exon inclusion remained 
high for two days followed by a graduate decrease (Fig. 4B, right). 
Figure 3. Effect of ASOs on alternative splicing of different exons of endogenous SMN2. SMA type I patient fibroblasts (GM03813) were transfected 
with 20 or 100 nM of selected ASOs in 6-well plates. The total RNA for splicing assay was isolated 24 h post transfection. Spliced products were ampli-
fied by RT-PCR with one of the primers being end-labeled. Annealing positions of primers are shown by bars. (A) Left panel depicts the diagrammatic 
representation of expected spliced products. Right panel shows the results of RT-PCR. Exon 7 skipped, exon 5 skipped and co-excluded products are 
marked. (B) Left panel depicts the diagrammatic representation of expected spliced products due to skipping of exon 5. Right panel shows the results of 
RT-PCR. Exon 5 included and exon 5 skipped products are marked. (C) Left panel depicts the diagrammatic representation of expected spliced products 
due to skipping of exon 3. Right panel shows the results of RT-PCR. Exon 3 included and exon 3 skipped products are marked.
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Figure 5. Confocal images confirming that treatment 
with short ASO (3UP8) promotes nuclear accumulation 
of SMN in SMA patient cells. The fibroblasts from SMA 
type I patient (GM03813) were cultured on coverslips 
and transfected with 40 nM of F8 (control) or 3UP8 
CY3-labeled ASOs. Cells were fixed 48 h after trans-
fection and stained with anti-SMN (Green) and anti-
ZPR1 (Red) antibodies. Cells transfected with ASOs 
were detected by Cy3 fluorescence and presented 
in pseudo-color (Cyan). DNA was stained with DAPI 
(blue). The scale bar is 10 mm.
Figure 4. Effect of the shortest stimu-
latory ASO (3UP8) on levels of cel-
lular proteins in SMA patient cells. 
(A) Western blot showing the effect 
of different ASOs. SMA type I patient 
cells (GM03813) were transfected with 
40 nM of selected ASOs and cells 
were harvested 48 h after transfection. 
Left panel represents the results of west-
ern blot of different proteins, whereas 
the right panel represents the results of 
RT-PCR. (B) Time course of 3UP8 effect 
on the levels of SMN and other factors. 
SMA type I patient cells (GM03813) 
were transfected with a single dose of 
40 nM of 3UP8 and harvested after 
every 24 h for six days. Left panel 
represents the results of western blot 
of different proteins, whereas the right 
panel represents the results of RT-PCR.
SMN-interacting protein, ZPR1 
(Fig. 5). It is known that ZPR1 
is required for accumulation of 
SMN in these sub-nuclear struc-
tures.56,57 Our finding that 3UP8 
is able to increase the number of 
gems confirms a proper assembly 
of SMN in the nucleus. This also 
marks the first evidence of a stimu-
latory response by a very short 
ASO leading to the massive macro-
molecular reorganization in the 
nucleus of a patient cell.
Discussion
SMA is the second most common genetic 
disorder of children and infants caused by insuf-
ficient levels of SMN protein due to the loss 
of the SMN1 gene. Presence of a defective 
gene, SMN2, makes SMA a unique genetic 
disease that could be avoided and possibly cured 
by redirecting SMN2 exon 7 splicing. Among 
several approaches to correct aberrant splicing, 
an ASO-based approach provides a superior 
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change in the RNA structure in the vicinity of the 5' ss. Such a 
structural change may help improve U1 snRNP recruitment and/
or the 5' ss recognition. We have previously shown that recruit-
ment of U1 snRNP at the 5' ss of exon 7 is a limiting step for 
SMN2 exon 7 inclusion.13,29 Our results also suggest that the 
catalytic core of splicing is not affected by a RNA:RNA duplex 
formed between an ASO and its target immediately downstream 
of the U1 snRNA binding site. However, dissociation of ASO 
from the target sequence through a helicase reaction during the 
catalytic core formation could not be ruled out. In this scenario, 
the same antisense will be recycled several times on different SMN2 
pre-mRNAs. This is an obvious advantage of short ASOs in an 
ASO-based therapy because frequency of drug (ASO) administra-
tion could be minimized.
Our work underscores the high target specificity of very short 
ASOs during RNA:RNA interactions. For instance, a single 
mismatch in the middle of the target caused a drastic decrease 
in the stimulatory response by 3UP8. On the contrary, longer 
ASOs tolerated this mismatch mutation due to a large duplex 
formed between an ASO and the target. Tolerance of mismatched 
mutations provides an inherent drawback and therapeutic risk 
associated with longer ASOs. Consistently, high concentrations of 
a 20-mer ASO (Anti-N1) targeting intron 7 produced an off-target 
effect on SMN2 exon 3 splicing, whereas identical concentrations 
of 3UP8 had no effect (Fig. 3C).
Owing to the high target specificity and an efficient antisense 
response by a short ASO, 3UP8 increased levels of SMN in SMA 
patient cells. It also restored levels of several key proteins that are 
generally downregulated in SMA (Fig. 4B). These include factors 
involved in snRNP biogenesis (Gemin 2 and Gemin 8) and RNA 
splicing (Tra2-b1 and hnRNP Q).38,55 hnRNP Q proteins have 
been also implicated in other aspect of RNA metabolism, such 
as RNA transcription, translation, stability and trafficking.53-55 
Increase in ZPR1 in 3UP8-treated cells suggests that a short 
ASO is capable of restoring SMN-interacting factors, reduced 
expressions of which are associated with the progressive loss of 
motor neurons.56,57 Despite a gradual decrease in the levels of 
SMN2 exon 7 inclusion after two days, high SMN levels were 
maintained for five days after single treatment with 40 nM 3UP8. 
These findings suggest a substantially longer half-life of SMN 
owing to the stabilization of SMN through association with itself 
and/or with other factors. Consistent with the restoration of the 
SMN-interacting partners, 3UP8-treated cells showed increased 
numbers of sub-nuclear bodies (gems) in the nucleus (Fig. 5).
Currently SMA has no cure, although several small compounds 
capable of increasing levels of SMN in SMA have been identi-
fied.23 Mechanisms of actions and side effects of these compounds 
remain unknown. Earlier ASO-based strategies promised high 
target specificity and focused on large ASOs in the anticipa-
tion that small motifs could not be targeted by small ASOs.42-49 
In general, literature is replete with studies using 15-mer or longer 
ASOs for modulation of alternative splicing. Our work provides 
the first evidence of high target specificity for a very short ASO 
and sets a unique precedence of pathogenic splicing modulation 
by RNA molecules less than half the size of the most reported 
alternative due to the anticipated target specificity. Size of an 
ASO is an important determinant in success of an ASO-based 
strategy. Despite the expected advantages, it is not known if very 
short ASOs could anneal to the target and bring desired changes 
in a sequence-specific manner, particularly at the low nanomolar 
concentrations.
Here we report an 8-mer ASO (3UP8) as the shortest ASO 
to correct the aberrant splicing of SMN2 exon 7 in SMA patient 
cells. To the best of our knowledge, this is the first report in which 
an 8-mer ASO is able to effectively correct aberrant splicing in a 
patient cell line. Identification of this ASO was achieved through 
a systematic approach of ultra-refined antisense microwalk in an 
intronic region adjacent to the 5' ss of exon 7. The 8-mer ASO 
exerts its stimulatory effect through binding to a GC-rich sequence 
(CUGCCAGC) spanning from the 7th to 14th position of intron 
7 (Fig. 1). Underscoring an evolutionary significance, this intronic 
region is not conserved between human and mice.42 CUGCCAGC 
target sequence seems to be highly accessible since low nanomolar 
concentrations of 3UP8 fully restores SMN2 exon 7 inclusion 
(Table 1). Consistently, the predicted secondary structure puts this 
target sequence in an internal loop flanked by terminal stem-loop 
structures (Fig. 1A).28
Our ultra-refined antisense microwalk with about 50 ASOs 
captured relative strength of multiple antisense targets that differed 
by a single nucleotide. As a consequence, it also revealed positions 
of high significance, wherein sequestering of the last five residues 
(CCAGC) of the GC-rich target was found to be absolutely 
required for the stimulatory response on SMN2 exon 7 inclusion 
(Table 1). Hence CCAGC residues could be considered as the 
core motif, analogous to the seed sequence of the micro-RNA 
target.50 However, unlike microRNAs that require assembly of a 
RNA-induced silencing complex (RISCs) on an 18-mer or longer 
sequence, our antisense response is solely based on the short 
RNA:RNA duplex. Based on the published reports, it is highly 
unlikely that protein factors could form a stable complex with a 
short RNA:RNA duplex. However, we cannot rule out the possi-
bility of secondary contacts that might have been affected.
The GC-rich target described here does not resemble any 
known binding motif of a splicing factor, although, it overlaps 
with the first five residues of ISS-N1, an intronic element that 
harbors two putative hnRNP A1 binding sites.42,43 The C residue 
at the first position (1C) of ISS-N1 is not the part of hnRNP A1 
motif, yet sequestering of this position was found to be absolutely 
necessary for the antisense response. Further, several ASOs that 
did not sequester 1C produced an inhibitory effect even though 
they fully sequestered both hnRNP A1 motifs (data not shown). 
These results suggest that the stimulatory response of ASOs is 
a combination of effects not necessarily caused by blocking of 
hnRNP A1 motifs.
Various mechanisms may account for the stimulatory response 
exerted by 3UP8. The most obvious among them is the strong 
target affinity of 3UP8 compared to an inhibitory factor that 
may transiently interact with the same target during the dynamic 
process of splicing. It is also possible that the RNA:RNA duplex 
formed between 3UP8 and the GC-rich target helps bring a subtle 
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AAA GG3') and 3'Exon6SMN (5'CAT ATA ATA GCC AGT 
ATG ATA GCC3') for SMN exon 5; 5'Exon1SMN (5'CTG TTC 
CGG CGC GGC ACA GGC CAG3') and 3'Exon4SMN (5'TCA 
CTT TCA TCT GTT GAA ACT TGG3') for SMN exon 3. PCR 
reactions were performed either in the presence of a trace amount 
of [a-32P] dATP (3,000 Ci/mmole) or with one of the primers 
being 5'end-labeled. Primers were end-labeled using [g-32P]ATP 
(3,000 Ci/mmole) and T4 polynucleotide kinase (New England 
Biolabs), followed by phenol:chloroform extraction and spinning 
through a Micro Bio-spin 30 Chromatography Column (Bio-Rad) 
to get rid of unincorporated [g-32P] ATP. Analysis and quantifica-
tions of spliced products were performed using a FPL-5000 Image 
Reader and Multi Gauge software (Fuji Photo Film Inc.,). Results 
were confirmed by at least three independent experiments.
Western blot analysis. Whole-cell extracts were prepared 
using ice-cold RIPA buffer (Boston BioProducts) supplemented 
with protease inhibitor cocktail (Roche Applied Science). Protein 
concentrations were determined using BSA Protein Assay Kit 
(Thermo Scientific). Cell extracts were resolved on a 10% (w/v) 
SDS-PAGE gel and transferred onto polyvinylidene fluoride 
(BioTrace PVDF) membrane (Pall Life Sciences). The following 
primary and secondary antobodies were used: mouse monoclonal 
anti-SMN (BD Transduction Laboratories), mouse monoclonal 
anti-hnRNP Q (Sigma), rabbit polyclonal anti-Tra2 (Abcam), 
rabbit polyclonal anti-b-actin (Sigma), horseradish-peroxidase-
conjugated secondary antibodies against mouse (Sigma) and rabbit 
(Jackson Immuno Research). Mouse monoclonal anti-Gemin 2 
and anti-Gemin 8 antibodies were kindly provided by Dr. Gideon 
Dreyfuss. Mouse monoclonal anti-ZPR was the same as described 
earlier.51,57 In most cases, the membranes were stripped (15 min 
at room temperature) using Restore western Blot Stripping Buffer 
(Thermo Scientific) and re-probed. The membranes were scanned 
using UVP BioSpectrum AC Imaging System (UVP). Signal inten-
sities were quantified using Vision works LS Image Acquisition 
and Analysis software (UVP). Results were confirmed by at least 
three independent experiments.
Immunofluorescence analysis. Patient fibroblasts (GM03813) 
were cultured on coverslips and transfected with 40 nM of F8 
(control) and 3UP8 CY3-labeled ASOs using Lipofectamine 
2000 as described above. Cell were harvested 48 hr post-transfec-
tion, washed, fixed and processed for immunofluorescence.51,57 
Double labeling (ZPR1/SMN) was carried out by sequential 
incubations with anti-SMN (clone 8, BD Transduction laborato-
ries), Alexa 633-conjugated anti-mouse IgG secondary antibody 
(Molecular Probes) and then with FITC-conjugated LG1 (anti-
ZPR1).51,57 The cover slips were mounted on slides using 
Vectashield with DAPI (Vector Laboratories) and examined by 
indirect immunoflourescence using LSM510 confocal microscope 
(Carl Ziess) equipped with 405 nm diode laser.
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ASOs. Compared to large ASOs that carry the inherent risk of 
partial sequestration of different kinds of small motifs and tolerate 
mismatch mutations, we show that the stimulatory activity of a 
small ASO is exclusively dependent upon the perfect match with 
a single motif that is uniquely located within an accessible region 
of a negative context. Short ASOs offer additional advantages 
including low cost of synthesis, ease of chemical modifications, 
reduced chances of immune response, and higher probability of 
crossing biological barriers.58 When promotion of exon inclusion 
is the goal, a short intronic target brings the desired benefits of 
non-interference with nuclear export and translation. Hence, our 
findings represent further advancement towards an ASO-based 
therapy of SMA and bring a unique perspective to our under-
standing of splicing regulation of a defective gene associated with 
a major genetic disease of children and infants.
Materials and Methods
Plasmids, cells and ASOs. Construction of SMN2 minigene 
is described earlier.35 Construct SMN2/64A contains a C-to-A 
mutation in SMN2 minigene and was generated by PCR using 
Phusion High-Fidelity DNA polymerase (New England Biolabs). 
HeLa cells were obtained from the American Type Culture 
Collection and were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS). Primary fibroblast cell line from SMA type I patient 
(Repository number GM03813) and a healthy control (Repository 
number AG06814) were obtained from Coriell Cell Repositories. 
These cells were maintained in MEM supplemented with 2 mM 
GlutaMAX-I and 15% FBS. All tissue culture media and supple-
ments were purchased from Invitrogen. RNA ASOs used in our 
study were synthesized by Dharmacon Inc., These ASOs incorpo-
rated 2'-O-methyl modification and phosphorothioate backbone 
(2OMePS) as described earlier.42
Transfections and in vivo splicing assays. Transient trans-
fections of cells with plasmid DNA and/or with ASOs were 
performed using Lipofectamine 2000 (Invitrogen) following the 
manufacturer’s recommendations. Briefly, cells were plated 24 h 
prior to transfection so that their density on the day of transfection 
was ~80%. Oligonucleotide concentration ranged from 1 to 100 
nM. In a given experiment, the total amount of oligonucleotide 
was maintained constant by adding the control oligonucleotide 
(5'TGA CAT CCA CTT TGC CTT TCT CTC3'). Total RNA 
was isolated at the indicated time points using Trizol reagent 
(Invitrogen). To generate cDNA reverse-transcription was carried 
out using SuperScript III Reverse Transcriptase (Invitrogen) and 
Oligo (dT) primer (Invitrogen). 1 mg and 3 mg of total RNA were 
used per 20 ml of reaction for amplification of minigene-specific 
and endogenous spliced products, respectively. Minigene-specific 
spliced products were identified using Taq polymerase (Invitrogen) 
and the pair of primers P1 and P2 for SMN2 minigenes.35 
For PCR amplification of endogenous exons the following 
primer combinations were used: N-24 and P2 for SMN exon 
7;42 5'Ex4 hSMN-RP (5'GGC CAA GAC TGG GAC CAG 
G3') and 3'SPL8 (5'TGG TGT CAT TTA GTG CTG CT3') 
or 5'Ex4last1192 (5'AGG GCC AAG ACT GGG ACC AGG 
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